^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CTAG1A expression

    i
    Other names: CTAG1A, Cancer/Testis Antigen 1A, LAGE2A, ESO1, Autoimmunogenic Cancer/Testis Antigen NY-ESO-1, Cancer/Testis Antigen 6.1, L Antigen Family Member 2, Cancer/Testis Antigen 1, LAGE-2, CT6.1, New York Esophageal Squamous Cell Carcinoma 1, Cancer/Testis Antigen 1-A, NY-ESO-1, CTAG1A, LAGE2B, CTAG1, LAGE2, CTAG
    Entrez ID:
    246100
    7ms
    Characterization of Cancer/Testis Antigens as Prognostic Markers of Ovarian Cancer. (PubMed, Diagnostics (Basel))
    The CCT4 up-regulation and PRAME mutations were correlated with a good prognosis for ovarian cancer, while higher levels of GAGE2A and CT45A1 mRNAs were correlated with a poor prognosis for ovarian cancer patients. Thus, GAGE2, CT45, CCT4, and PRAME cancer/testis antigens can be considered as potential prognostic markers for ovarian tumors, and GAGE2, CCT4, and PRAME were revealed to be correlated with the prognosis for ovarian cancer patients for the first time.
    Journal
    |
    CTAG1B (Cancer/testis antigen 1B) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma) • ACRBP (Acrosin Binding Protein) • CTAG1A (Cancer/Testis Antigen 1A) • MAGEC1 (MAGE Family Member C1) • KDM5B (Lysine Demethylase 5B) • MAGEA1 (MAGE Family Member A1)
    |
    CTAG1A expression